This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dr. Reddy's Inks Deal to Sell Neurology Branded Products
by Zacks Equity Research
Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.
Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi
by Zacks Equity Research
Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230
by Zacks Equity Research
Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
Zynerba Up on Second Patent for Cannabidiol Candidate in 2019
by Zacks Equity Research
Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.
Novavax' Shares Drop as FDA Advises Another Study for Resvax
by Zacks Equity Research
FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.
Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug
by Zacks Equity Research
Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
Incyte Begins Phase III Study for Treatment of Duct Cancer
by Zacks Equity Research
Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
bluebird's Zynteglo Gets EU Conditional Marketing Approval
by Zacks Equity Research
bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.
Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down
by Zacks Equity Research
Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.
uniQure (QURE) Jumps: Stock Rises 8.9%
by Zacks Equity Research
uniQure (QURE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Alnylam Initiates Phase I Study on Hypertension Candidate
by Zacks Equity Research
Alnylam (ALNY) initiates phase I study on ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen for the treatment of hypertension in high unmet need populations.
Fibrocell Up on FDA Designation for Gene Therapy Candidate
by Zacks Equity Research
Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.
Amarin Rises on Priority Review for Vascepa Label Expansion
by Zacks Equity Research
Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.
Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down
by Zacks Equity Research
Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.
Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why?
by Zacks Equity Research
Epizyme's (EPZM) share price soars more than 100% year to date. The company is progressing well with its pipeline candidate, Tazmetostat.
Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business
by Zacks Equity Research
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.
Guardant Health (GH) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Guardant Health (GH) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
by Zacks Equity Research
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1
by Zacks Equity Research
Affimed (AFMD) exceeds earnings and sales estimates in the first quarter of 2019. The company also plans to focus its research and development investments.
OncoSec Medical (ONCS) Looks Good: Stock Adds 6.6% in Session
by Zacks Equity Research
OncoSec Medical (ONCS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
BioMarin (BMRN) in Focus: Stock Moves 7.5% Higher
by Zacks Equity Research
BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion
by Zacks Equity Research
Regeneron's (REGN) Eylea gets FDA approval for label expansion to include patients of all stages with diabetic retinopathy.
Twist Bioscience (TWST) Catches Eye: Stock Jumps 8%
by Zacks Equity Research
Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.